Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
AstraZeneca
M.D. Anderson Cancer Center
University of Alabama at Birmingham
National Cancer Institute (NCI)
AbbVie
Genmab
AstraZeneca
Neonc Technologies, Inc.
Imunon
Imunon
AbbVie
Ohio State University Comprehensive Cancer Center
Memorial Sloan Kettering Cancer Center
Eli Lilly and Company
Swiss GO Trial Group
TORL Biotherapeutics, LLC
GlaxoSmithKline
Zhejiang Cancer Hospital
Women's Hospital School Of Medicine Zhejiang University
Avenzo Therapeutics, Inc.
Shanghai Shengdi Pharmaceutical Co., Ltd
M.D. Anderson Cancer Center
AstraZeneca
Maastricht University Medical Center
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Eli Lilly and Company
AGO Study Group
University Health Network, Toronto
AstraZeneca
The University of Hong Kong
The University of Hong Kong
University of Pittsburgh
The University of Hong Kong
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Shandong Cancer Hospital and Institute
Akeso
Huabo Biopharm Co., Ltd.
Leiden University Medical Center
Anhui Provincial Cancer Hospital
K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
University of California, San Diego
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University College, London
Suzhou Zelgen Biopharmaceuticals Co.,Ltd